Obviously iPSCs are cell models and not the actual cells you want, but they are usually better than immortalized cell lines or cadavers.
Obviously iPSCs are cell models and not the actual cells you want, but they are usually better than immortalized cell lines or cadavers.
He's getting at the fact that we've known how to induce pleuropotency for quite some time (I did some reach in this in orthopaedics in 2010), which is what the article title is misleading us to believe.
My point is that iPSCs are still quite useful in pharmaceutical research and development - a therapy adjacent area.
Improved cell models are still a pretty big deal. Part of the reason for high costs and failure rates in pharma R&D is that experimental models we use to generate data are imperfect. Better models = better data = better decisions.
I am not sure why everyone is convinced that they will not be very useful in therapies...